News
WGS
77.08
+10.76%
7.49
GeneDx Holdings Corp. (NASDAQ:WGS) Analysts Are Pretty Bullish On The Stock After Recent Results
Simply Wall St · 3d ago
Alger Small Cap Focus Fund Q2 2026 Portfolio Review
Seeking Alpha · 3d ago
Cathie Wood’s ARK buys $23M SpaceX, $17M Nvidia; offloads Roblox, Palantir
Seeking Alpha · 4d ago
Mid-cap Sell streak: Stocks trapped longest in bearish Quant ratings
Seeking Alpha · 4d ago
Cathie Wood Cashes In on Palantir’s Post-Earnings Surge
TipRanks · 4d ago
GeneDx Holdings Corp. Earnings Call Highlights Risks
TipRanks · 5d ago
GeneDx (WGS) Stock Climbs On Strong Margins As Reimbursement Lags
Simply Wall St · 5d ago
Analysts Offer Insights on Healthcare Companies: Design Therapeutics (DSGN), Certara (CERT) and GeneDx Holdings (WGS)
TipRanks · 5d ago
GeneDx Earns Buy Rating as Massaro Sees High‑Margin Exome Growth Driving Profitability, Sets $90 Price Target
TipRanks · 5d ago
Kyle Mikson Boosts GeneDx Price Target to $90 and Reaffirms Buy Rating on Strengthened Financial Outlook
TipRanks · 5d ago
Piper Sandler Sticks to Its Buy Rating for GeneDx Holdings (WGS)
TipRanks · 5d ago
GeneDx Holdings Is Maintained at Buy by Canaccord Genuity
Dow Jones · 5d ago
GeneDx Holdings Price Target Raised to $90.00/Share From $75.00 by Canaccord Genuity
Dow Jones · 5d ago
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90
Benzinga · 5d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 5d ago
GeneDx price target raised to $90 from $75 at Canaccord
TipRanks · 5d ago
GeneDx Holdings Price Target Maintained With a $90.00/Share by BTIG
Dow Jones · 6d ago
BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target
Benzinga · 6d ago
GeneDx Holdings (WGS) Is Up 9.7% After Beating Q2 Estimates And Reaffirming 2026 Outlook - Has The Bull Case Changed?
Simply Wall St · 6d ago
CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
Benzinga · 6d ago
More
Webull provides a variety of real-time WGS stock news. You can receive the latest news about GeneDx Holdings Corp through multiple platforms. This information may help you make smarter investment decisions.
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Genomic sequencing tests include whole genome sequencing, whole exome sequencing, prenatal genetic testing, targeted testing, pediatric neurology, general pediatrics, geneticists and genetic counsellors, and others. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.